For patients with stage 2 or greater bladder cancer, care transitions linked with treatment delay
the ONA take:
According to a new study published in the Journal of Urology, researchers have found patients with stage 2 or higher urothelial carcinoma who underwent a care transition were more likely to experience a delay in treatment of 3 months or greater.
For the study, researchers sought to investigate whether changing hospitals between diagnosis and therapy for patients with muscle invasive bladder cancer would experience a delay in timely treatment. They identified 22,251 patients with stage 2 or greater urothelial carcinoma treated between 2003 and 2010 from the National Cancer Database.
Patients were considered to have underwent a care transition if they experienced a change in hospital between diagnosis of cancer and treatment with radical cystectomy or the initiation of neoadjuvant chemotherapy. Of all patients identified, 14.2% experienced a treatment delay of 3 months or more.
This proportion increased from 13.5% between 2003 and 2006 to 14.8% between 2007 and 2010 (P = 0.01). Of the patients who underwent a care transition, 19.4% experienced a treatment delay of 3 months or greater versus 10.7% who were diagnosed and treated at the same facility. The authors suggest that expediting care transitions at the time of hospital referral may improve the quality of care for patients with muscle invasive bladder cancer.
Patients with stage 2 or higher urothelial carcinoma who underwent care transition more likely to experience a delay in treatment.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|